WW domains are small b-sheet motifs that are involved in intracellular signalling through the recognition of proline-rich or phosphorylated linear peptide sequences. Here, we describe modification of this motif to provide a framework for engineering the side chains exposed on its concave surface. This non-natural scaffold incorporates an additional tryptophan, has a shorter loop 1 and supports modification of 25% of the natural protein to form a novel affinity reagent. We demonstrate the utility of this structure by selecting a high-affinity binder to the extracellular region of human vascular endothelial growth factor receptor isoform 2 (VEGFR-2) from a library of modifications, using a cell-free molecular display platform, CIS display. The isolate has low nanomolar affinity to VEGFR-2 and inhibits binding of human VEGF to its receptor with nanomolar activity. The structure is amenable to cyclisation to improve its proteolytic stability and has advantages over larger protein scaffolds in that it can be synthesised chemically to high yields offering potential for therapeutic and non-therapeutic applications.
Introduction
Protein domains are natural modulators of biological function through ligand binding. These domains may be engineered in order to produce altered activities and novel affinity reagents. Typically, engineering efforts focus upon modification or randomisation of the loops in globular structures. Antibody variable domains are the most widely studied affinity ligands, but other structures have been developed to obtain new and useful properties (Hoogenboom, 2005; Hosse et al., 2006) . WW domains are small peptide domains, 40 amino acids in length, which bind linear peptide sequences and mediate intracellular protein -protein interactions (Staub and Rotin, 1996) . The name 'WW domain' refers to a pair of conserved tryptophan (W) residues known to be essential for the formation of the structure. However, there are rare exceptions to this rule, where a phenylalanine or a tyrosine residue substitutes one of the tryptophan residues. Since WW domains are relatively small structures, they have served as good models for understanding the folding energetics of small b-sheet proteins. Several structures of single or paired WW domains have been determined, with and without a bound ligand, and have been shown to adopt an anti-parallel three-stranded b-sheet (or 'b-meander') with a cup-shaped binding surface. Generally, these peptide ligands adopt an extended conformation in the binding groove of the WW domain in a manner similar to a rope being loosely held by the grip of a hand although, in one known structure, the peptide ligand is looped across the palm (Huang et al., 2000; Kanelis et al., 2001; Wintjens et al., 2001; Wiesner et al., 2002; Meiyappan et al., 2007) .
The binding specificity of the WW domain has led to the classification of these domains into five groups dependent upon the ligand sequence. group I domains recognise PPXY motifs; group II domains recognise PPLP motifs; group III domains bind proline-rich stretches containing methionine and glycine residues (PGM motif ); group IV domains bind phosphoserine and phosphothreonine residues; and group V domains bind stretches of proline that are rich in arginine . Recently, 42 WW domains have been studied by nuclear magnetic resonance spectroscopy and peptide library screens, leading to further classification of WW peptides into six groups based upon their recognition of proline, phosphoserine and threonine peptide motifs (Otte et al., 2003) .
Two WW domains from group I (Nedd4.3, hYAP) have been modified for altered ligand specificity (Dalby et al., 2000; Kasanov et al., 2001) . hYAP has been displayed on the surface of phage particles to select improved binding to a known peptide ligand containing the consensus motif PPXY from a combinatorial library. In silico approaches have identified new group I WW domains for binding to peptide libraries derived from consensus motifs and identified the coevolving contact residues as L 3 P 4 G 6 E 8 I/V 21 D/N 22 H 23 T 28 . No group II or IV domains were identified that bound these peptide libraries Socolich et al., 2005) .
The group IV WW domain, Pin1, has previously been mutated in order to modulate its binding and stability, and was shown to bind exclusively to phosphorylated serine/ threonine targets ( poS/poT), and not to phosphotyrosine peptides or non-phosphorylated target sequences. In fact, the tightest binding was recorded for poT peptides from the sequence wwpoTPP (where w is a hydrophobic residue and P is proline) (Jiang et al., 2001; Otte et al., 2003) . Introduction of a single or a pair of tryptophan residues into the wild-type Pin1 sequence as well as substitution of its native loop with the sequence of loop1 from the FBP WW domain resulted in an improved thermostability. However, the binding affinities of these engineered Pin1 WW domains for their natural peptide ligands were reduced below detectable limits (Jäger et al., 2006 (Jäger et al., , 2007 (Jäger et al., , 2009 .
Despite the wealth of mutagenesis data available for WW domains, it has not been shown that the WW domain can be engineered to bind extracellular ligands. Here, we demonstrate that the Pin1 sequence can be used as a framework for engineering and can be displayed on an in vitro molecular display system, CIS display. Using this system, high-affinity, folded, stable, active peptides have been identified via selection against an extracellular protein. In addition, the selected WW domain has been chemically synthesised and modified to add further stability. This approach has potential for applications in therapy or as diagnostic tools or affinity reagents.
Materials and methods

DNA library construction
CIS display library construction was performed as previously described (Odegrip et al., 2004; Eldridge et al., 2009) . Library primers were designed to alter the appropriate sequence of the Pin1 WW domain. The tac-PinLib-RepA-CIS-ori polymerase chain reaction (PCR) construct was prepared as follows; the RepA-CIS-ori region was amplified by PCR from the R1 plasmid (GenBank accession no. V00351) using primers 1StepRepFor and M13rev. A second PCR was then performed on RepA-CIS-ori with a long primer encoding the Pin1 domain and GSGSS linker (Pin1 library primer) and primer DigLigRev. Finally, the tac promoter was appended upstream of the nucleic acid framework library in a third PCR using primers 131mer and DigLigRev as before. All primers mentioned are listed in Table I . Correct library assembly was confirmed by sequencing.
In vitro transcription, translation and selection
Generally, in vitro transcription and translations (ITT) were carried out as previously described (Odegrip et al., 2004; Eldridge et al., 2009) . After expression, the samples were diluted 5-fold in selection buffer containing 2% bovine serum albumin (BSA) and 0.1 mg/ml herring sperm DNA, in phosphate-buffered saline (PBS).
Two micrograms of VEGFR-2-Fc fusion (R&D Systems, Abingdon, UK) comprising the vascular endothelial growth factor receptor isoform 2 (VEGFR-2) target ligand was immobilised on 20 ml TALONw magnetic beads (Invitrogen, Paisley, UK) in PBS. The coated beads were washed three times with 1 ml PBS-T (PBS, 0.1% Tween-20) and twice with PBS. The diluted ITT reactions were added to the coated beads and incubated for 1 h at room temperature (RT) while mixing on a rotary mixer. The beads were then removed from the selection buffer and washed four times with PBS-T, and once with PBS (5 min/wash). Bound DNA was eluted from the beads by incubation in 1Â ThermoPol buffer, at 658C for 10 min. Half of the eluted material was added to a recovery PCR reaction where the N-terminal library region was amplified using primers R1RecFor and NotRecRev (Table I ). All recovered PCR products were reattached to the RepA-CIS-ori region by ligation, as previously described (Odegrip et al., 2004; Eldridge et al., 2009) , and further amplified with primers R1RecFor and DigLigRev, thereby producing input DNA for the next round of selection.
For subsequent rounds of expression, screening and selection, the resulting DNA from the preceding round was added to a fresh ITT mixture and the selection process was repeated. The process was repeated a further three times (i.e. a total of four rounds of expression, screening and selection), to enrich the pool of binding clones. To increase the selection pressure in the second and subsequent rounds of selection and favour the most desirable peptides, selection conditions were modified as shown in Table II . Nested forward primers R1RecFor and Tac6 (Table I) were used in the third and fourth rounds of the selection procedure, respectively.
Binding analysis by enzyme-linked immunosorbent assay
The output from the fourth round of selection was digested and ligated into a phagemid vector, and produced in phage as described by Odegrip et al. (2004) . Enzyme-linked immunosorbent assays (ELISAs) were then performed to screen for modified WW domain peptides that bound the target ligand. Maxisorp plates were coated with 50 ng per well of VEGFR-2 in PBS overnight at 48C. After blocking the plates with blocking buffer (2% BSA in PBS-T) for 1 h, phages displaying the selected clones were diluted in blocking buffer, added to the plates and incubated for 1 hr at RT. WW domain binders were detected using horseradish peroxidase-conjugated anti-M13 antibody (GE Heathcare, Buckinghamshire, UK) and SureBlue TMB peroxidase substrate (Insight Biotechnology, Middlesex, UK) followed by detection and reading at 450 nm in an absorbance plate reader. A selection of positive clones, showing a high signal for VEGFR-2, were sequenced (Cogenics Ltd, Essex, UK) to obtain the modified WW domain peptide sequences. 
Chemical synthesis
Selected modified WW domain peptides were chemically synthesised using standard Fmoc/tBu protocols. N-terminal biotinylation was conducted on the solid phase, after a final Fmoc deprotection step. Similarly, for the cyclic peptides, cyclisation was accomplished on the resin using 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (5 equivalents to peptidyl-resin) and diisopropylethylamine (10 equivalents to peptidyl-resin). After a final trifluoroacetic acid (TFA) cleavage step (TFA:TIS:H 2 O as 95 : 2.5 : 2.5), peptides were purified using a reverse-phase C18 column to .90% purity. mass spectrometer (Shimadzu, Milton Keynes, UK), pooled and lyophilised for storage. For disulphide-bridged peptides, oxidation was accomplished by dissolving the crude purified peptides in an aqueous solution containing 20% dimethyl sulfoxide (v/v) and 5% AcOH (v/v) so that the peptide concentration did not exceed 0.5 mg/ml. The pH was then adjusted to between 6.0 and 6.5 with liquid ammonia, and the solution stirred at RT, typically for 24-48 h (Domingo et al., 1995) . The formation of the disulphide bond was monitored by following the shift in retention time by highperformance liquid chromatography (HPLC), and the change in mass as monitored by mass spectrometry (following purification) concomitant with the change from a linear to cyclic peptide.
Circular dichroism
Lyophilised WW-B1 was resuspended in 10 mM sodium phosphate buffer, pH 5.0 to a concentration of 0.8 mM. Far-ultraviolet (UV) spectra were measured on an Aviv Model 410 spectrometer, using a 1-mm cuvette (Hellma, Essex, UK) and the following parameters; 0.5-nm intervals, 1-s averaging time and a 1-nm bandwidth. Five scans were taken in total at each temperature and the results averaged followed by buffer subtraction. The CD scans were plotted using Aviv model 4.10 software, and the data were converted to mean residue ellipticity (deg cm 2 dmol
21
).
Affinity measurement
Real-time binding assays between the chemically synthesised peptides and human VEGFR-2-Fc fusion, VEGFR-1-Fc fusion or VEGFR-3-Fc fusion (R&D Systems) were performed using biolayer interferometry with an Octet Red system (Fortebio, Menlo Park, CA, USA). The respective biotinylated peptide was immobilised on streptavidin biosensors at 20-50 ng/ml in PBS followed by a blocking step in Superblock (Thermo Scientific, Loughborough, UK). Association curves were obtained by incubating peptide-coated biosensors with varying concentrations of the respective receptor target (1-100 nM in Superblock), and dissociations were detected by incubating in Superblock. The data were fitted from steady state equilibrium data using Octet Data Analysis 6.3 software (ForteBio).
Competition assay
A Nunc Maxisorp plate was coated with 50 ng/well VEGF-A (R&D Systems, 1 mg/ml in PBS) and incubated at 378C for 2 h. The wells were blocked with 200 ml PBS containing 2% BSA for 30 min at RT. VEGFR-2-Fc (1.25 ng) was pre-incubated with varying concentrations of the chemically synthesised WW peptide (10 mM to 0.06 nM) in 100 ml PBS for 40 min at RT. The pre-incubated complexes were diluted in 100 ml 4% BSA in PBS, added to the VEGF-coated ELISA plate and incubated at RT for 1 h. The plate was then washed three times with PBS-T and twice with PBS. Next, 50 ml/well penta His-HRP (QIAgen, 10Â concentrate diluted 1 : 2000 in 2% BSA in PBS) was added to each well and incubated at RT for 1 h, prior to washing as before. ELISA signals were detected as previously described. The assay was repeated twice and average signals plotted.
Stability assay in mouse plasma
Each peptide was diluted in mouse plasma (Harlan, UK) to a final concentration of 250 mM and incubated at 378C for up to 40 h. Samples were taken at regular intervals and the reaction quenched by adding twice the volume of 100% ethanol and incubating at 2208C for at least 1 h. The plasma samples were then centrifuged at 16 500 g for 10 min to remove any residual plasma impurities, and analysed directly by HPLC using a SunFire C18 column (Waters, Hertfordshire, UK) and a 10-50% gradient of buffer B (0.1% TFA, 5% water in 95% acetonitrile) into buffer A (0.1% TFA in water) over 20 min. Fractions were collected and analysed by mass spectrometry. The amount of intact peptide remaining at each time-point was quantified by calculating the percentage area of the intact peptide peak by integration of the absorbance traces at 215 nm, plotting against time and fitting to a one-phase exponential decay equation using Prism (GraphPad Software Inc., USA), to obtain the half-life in plasma.
Results
Library design
An alignment of Pin WW domains was created from different organisms (Fig. 1) to display the high conservation of sequences within this domain; most variation occurs at the N-terminus although proline and glycine residues are conserved to maintain the turn before the first b-strand. The domain contains at least 12 conserved amino acids which contribute both to the structural integrity of the domain and to ligand binding. These are Leu7, Trp11, Ser16, Ser18, Tyr23, Tyr24, Asn26, Thr29, Ser32, Trp34, Glu35 and Pro37. Positions 11, 26 and 37 have been identified in an artificial WW peptide as important for the hydrophobic core of the domain and 23 and 34 as necessary for the proline pocket Socolich et al., 2005) .
In our design, all these residues were therefore maintained, except for Ser 18 and Tyr23. Tyr23 is important for binding peptides containing a poS/poTP motif as it forms an aromatic clamp that contacts the proline residue at þ1 position to the phosphoserine or phosphothreonine residues. However, it was decided to use this as a library position as we did not require exclusive binding to phosphate-containing sequences (Lu et al., 1999; Wintjens et al., 2001 ). In addition, the Pin1 
Selection of WW domain against VEGFR-2 using CIS display WW domain framework was modified by inclusion of a third tryptophan residue at position 15. The latter has been shown to form non-hydrogen bonding Trp -Trp pairing with either of the other conserved tryptophans, increasing the melting temperature (T m ) of the domain from 59 to 638C (Cochran et al., 2001 , Jäger et al., 2007 . Although Loop 1 joining the first and second b-strands of the Pin1 WW domain adopts a rare (4 : 6) loop conformation, the (3 : 5) type-I G1 bulge turn is favoured within WW domain family members. Grafting the shortened FBP28 loop 1 sequence onto the Pin1 WW domain has been shown to improve the T m of the structure by 18.58C (Jäger et al., 2006) . Consequently, loop 1 was modified by removing one residue (Ser19) and mutating Arg17 and Ser18 to library positions (Fig. 2) . Residues within this loop have both functional and structural roles. In particular, Ser16-Arg17 in the Pin domain may provide an energetically acceptable interface for poSer/poThr-Pro and Ser19 contributes backbone-backbone hydrogen bonding with Ser16 and Arg21 (Verdecia et al., 2000; Jäger et al., 2001 ). The role of Ser18 is less appreciated but, since our aim was to modify the binding interface to target non-canonical ligands, it was appropriate to alter these conserved residues to library positions. Further residues on the concave surface of the domain, which form part of a hydrophobic cluster and a recognition surface for natural peptide ligands, were then chosen for randomisation (Fig. 3) . Residues Arg14, Ser16, Arg17, Tyr23, Phe25, Ser32 and Trp34 are known to be involved in binding a phosphorylated peptide from RNA polymerase II large subunit's C-terminal domain and all except Ser16 and Trp34 are accommodated in the library (Verdecia et al., 2000) . In total, 9 out of 23 positions (X 1 -X 9 ) on this surface were mutated (Figs. 2 and 3) . Selected residues that form part of the loops (X 3 , X 4 and X 9 ) were conservatively mutated to give a greater propensity for turns. The codons chosen for these positions are VVM (where V is A, C, G and M is A or C), which encode any of 12 amino acids (i.e. A, G, N, K, D, E, R, T, S, P, H and Q). The remaining mutations were NNB codons, which encode the full amino acid repertoire.
Therefore, the designed scaffold differs from that of the natural Pin1 sequence in the following features; loop 1 of the wild-type sequence was shortened by one amino acid, Met15 was substituted for a Trp residue, and nine of the remaining amino acid positions were randomly mutated. To express the modified Pin1 WW domain peptide in the CIS display library, the framework nucleic acid library includes a sequence that encodes a GSGSS amino acid linker at the C-terminus of the WW domain peptide and links it to the N-terminus of the RepA protein. An MA amino acid sequence was placed at the N-terminus of the WW peptide to encode for an NcoI site, used for cloning. The theoretical library diversity was 1.1 Â 10 11 (20 6 Â 12 3 amino acids; 48 6 Â 18 3 codons).
Selection and screening against an extracellular target-VEGFR-2
Selections were performed against the extracellular region of VEGFR-2 fused to human Fc. Four cycles of panning were employed, using the conditions in Table II , to enrich binding clones. Following the selection process, 48 clones were screened by phage ELISA against VEGFR-2 using BSA as a negative control. This screen revealed a number of binding clones for VEGFR-2 (data not shown). DNA sequencing of 13 positive clones revealed that over-represented sequences are present; the sequences of clones B1 and E1 appear two and seven times, respectively (Fig. 4) . Clones B1, E1, G3, B4, H4 and A1 are unique. Clones B1, E1, G3 and B4 are identical in the side chains selected in the library positions and only differ by a point mutation outside the randomised positions. These point mutations are believed to have been introduced during the four cycles of the PCR recovery process of CIS display. The specificity of four clones (A1, B1, E1 and H4) selected for binding to VEGFR-2 was assayed in an ELISA against a variety of non-target peptides/proteins. Clone H6 was selected from the primary screen as a non-binder to VEGFR-2 and was used as a negative control. This analysis demonstrated that clones B1, E1 and H4 are highly specific for VEGFR-2 and did not bind to human IgG, HSA, an enzyme or a mouse IgG (Fig. 5) .
Circular dichroism
Clone B1 (WW-B1) was synthesised as it displayed the highest signal for binding to VEGFR-2 over the background. To determine whether the synthesised WW-B1 peptide was folded, far-UV spectra were recorded at different temperatures using circular dichroism (CD). At 258C, WW-B1 demonstrated CD spectra characteristic of WW domains with a maximum at 227 nm (Fig. 6) . The peak is attributable to the Fig. 5 . Specificity of the modified WW domain peptides selected to bind to VEGFR-2 as assessed by ELISA. The modified WW domain peptides were tested against a plurality of target and non-target ligands: VEGFR-2 (black column); human IgG (narrow cross-hatch column); a monoclonal antibody (speckled column); an enzyme (light grey column); and human serum albumin (wide cross-hatch column). The white column is a blocked well control. Fig. 3 . The high-resolution surface of the WW domain of Pin1: (A) the residues used as library positions are shown as sticks and labelled and (B) the putative ligand-binding surface is displayed. Both images were created using the nuclear magnetic resonance structure 1I6C (Wintjens et al., 2001) and PyMol software (Schrödinger, Camberley, UK). Surface residues are displayed in light grey and the protein backbone in dark grey. Fig. 4 . Sequence alignment of the WW domain peptides selected to bind to VEGFR-2. An X in the Pin1 sequence illustrates the residues that were diversified by mutation in the naïve WW domain library.
Selection of WW domain against VEGFR-2 using CIS display aromatic content of the peptide in a folded conformation and notably disappears at 908C, which demonstrates unfolding at this temperature. However, the peptide is able to reform its structure after heating to 908C and then cooling to 258C (Koepf et al., 1999; Jäger et al., 2007) .
Affinity and half-life measurement of WW-B1
In the affinity and activity experiments, the wild-type Pin1 WW domain (WW-Pin1) was also synthesised as a negative control. The dissociation constant for the interaction between WW-B1 and VEGFR-2 was determined to be 44 nM by steady state analysis (Table III) . The non-selected WW-Pin1 displayed no measurable binding to VEGFR-2 (data not shown).
To ascertain whether WW-B1 is specific for VEGFR-2 or is capable of binding to other VEGF receptors, the binding experiment was also performed with VEGFR-1 and VEGFR-3. Data revealed a dissociation constant of 88 nM for WW-B1 binding to VEGFR-1, while no binding was observed with VEGFR-3 (data not shown). These results correlate well with the known function of VEGF-A, which is also capable of binding to both VEGFR-1 and VEGFR-2, but not VEGFR-3 to induce angiogenesis (Whitaker et al., 2001; Soker et al., 2002; Holmes et al., 2007) .
A competition ELISA was performed to establish whether WW-B1 could directly compete with the natural ligand VEGF-A for binding to VEGFR-2. The results demonstrate that WW-B1 strongly inhibits the binding of VEGFR-2 to VEGF-A with an IC 50 value of 54.5 + 1.1 nM (Fig. 7) . This indicates that the binding epitope on VEGFR-2 for WW-B1, may overlap with the binding site for VEGF-A. In contrast, the WW-Pin1 peptide has essentially no effect on the binding of VEGFR-2 to VEGF-A.
Stability and cyclisation
In order to understand the susceptibility of the scaffold to proteolysis we studied the in vitro half-life in mouse plasma. We have previously found that rodent plasmas are more active than human plasma samples (Eldridge et al., 2009) and therefore indicate sensitive sequences better. Using this assay, we determined the half-life of WW-B1 to be 7 h after monitoring the degradation for a total of 40 h (Table III) .
To further improve the resistance of WW-B1 to proteases, the WW-B1 scaffold was engineered for cyclisation by examining the structure in silico. Homology modelling, based on the nuclear magnetic resonance (NMR) structure 1I6C of the wild-type Pin1 WW domain, was used to create a model structure of WW-B1, using Andante (Smith et al., 2007) . As shown in Fig. 8 , two separate sites appeared to be of optimal distance for introducing a cyclic bond; (A) between Lys6 near the N-terminus and Pro36 near the C-terminus (cycB1_6 -36), and (B) between Glu4 near the N-terminus and Thr28 on loop 2 (cycB1_4 -28). As a first step, we elected to introduce the cyclic constraint in the form of a disulfide bond.
To create each cyclic structure, the sequence of WW-B1 was altered to substitute the chosen amino acids (Lys6 þ Pro36 and Glu4 þ Thr28) with a cysteine residue. During synthesis, the formation of the disulphide bond was followed using the retention time in HPLC. The retention time changed from 18.6 to 17.6 min, for cycB1_4-28, and from 18.7 to 18.0 min for cycB1_6 -36, and the masses of the purified peptides were verified by mass spectrometry. Each peptide was incubated in mouse plasma as described for WW-B1 to explore whether cyclisation had increased the half-life of the scaffold. The cyclic peptide 4 -28 showed a greater half-life than WW-B1 as monitored by HPLC and integration of the peak from the intact peptide (Table III) . The estimated half-life for cycB1_6-36 was the same as that of WW-B1 (7 h). In contrast, cyc-B1_4 -28 displayed a much greater half-life of 18 h. Data from the analysis of the masses from the cleaved products show that for all peptides, the main cleavage sites are most likely caused by trypsin or trypsin-like enzymes, as the cuts occur after a Lys or Arg residue.
We then verified binding to VEGFR-2 to investigate whether the substitution to Cys residues and the subsequent cyclisation had any deleterious effects on the binding surface of the peptide. The two cyclic peptides were tested using the same conditions as those used for the selected peptide WW-B1 and were found to be capable of binding to The dissociation constant for each interaction was measured using biolayer interferometry.
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The half-life was measured in mouse serum over 24 h.
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VEGFR-2 in the low nanomolar range. This is comparable with the binding calculated for WW-B1 with VEGFR-2 ( Table III ) and confirms that the disulphide bridge did not have a negative impact on activity.
Discussion
In this work, we have engineered a small WW scaffold and altered its specificity so that it binds with high affinity to a non-canonical target. The natural binding ligands for WW domains are linear proline-rich or phosphorylated peptides; in particular, Pin1 requires a poS/poTP motif for binding and had not previously been shown to bind non-phosphorylated peptides or proteins.
The extracellular region of VEGFR-2 is not a natural target of Pin1 and is also non-phosphorylated. Selection of our designed scaffold against a construct of VEGFR-2 consisting of its seven extracellular domains yielded specific, potent binders; it is the first time that a group IV WW domain such as Pin1 has been demonstrated to bind an unphosphorylated peptide sequence. Furthermore, the affinity of the interaction of one binder, WW-B1, was measured to be in the nanomolar range for VEGFR-2. WW-B1 is also capable of disrupting the interaction of VEGFR-2 with its natural ligand VEGF-A, as shown in the results from competitive inhibition experiments. Where binding affinities have been measured (e.g. by tryptophan fluorescence emission spectroscopy), for either natural or mutant WW domains with their target ligand, the affinities have invariably been found to be no stronger than 1 mM (Pires et al., 2001; Fedoroff et al., 2004; Kanelis et al., 2006) . For example, the affinities of the wild-type Pin1 WW domain against its natural target ligands, e.g. cell division control Cdc2 phosphatase, were measured as ranging from 7.7 to 126 mM (Verdecia et al., 2000) . Such binding affinities are weaker than is typically desired for use as diagnostic tools or as therapeutics (Wintjens et al., 2001) .
Our study suggests that the surface of the domain can be modified such that it can participate in high-affinity interactions but because of the transient and promiscuous nature of intracellular interactions, the peptide binding surface of the WW domain has evolved to possess an affinity that is functionally tuned. Unlike extracellular processes, where proteins are expressed and secreted into an extracellular environment, often having to mediate distal responses with exquisite specificity, thus requiring nanomolar or higher affinities, those within the cell tend to have a lower affinity and lower fidelity. Therefore, in our design, we modified nine positions on the surface of the domain, 25% of the total content, in order to maximise the binding surface for high-affinity recognition. It is also worth noting that a non-library mutation from Gln in the wild-type domain to an Arg residue at position 33 in the sequence of the selected WW-B1 was also observed. The impact of this modification on hydrogen bonding to the carboxyl group of Lys6 is not known. Interestingly, an Arg residue is present in the sequence of Magnaporthe oryzae (Fig. 1) , indicating that this mutation is naturally accommodated and may be advantageous.
Nevertheless, the change from the wild-type Pin1 domain, that coordinates weak intracellular interactions, to an engineered domain that offers an increased binding capable of disrupting higher affinity protein -protein interactions, represents a gain that is highly desirable when designing new Fig. 8 . Two different sites for cyclisation displayed on the modelled WW-B1 structure. The WW-B1 structure was created by homology modelling based on PDB 1I6C, using the Andante package (Smith et al., 2007) . A cyclic bond was engineered between (A) Lys 6 and Pro 36 and (B) Glu 4 and Thr 28. These residues were mutated to Cys in order to form a disulphide bond to cyclise each structure. The distance between the two residues in each structure was measured using Discovery studio 3.0 (Accelrys, Cambridge, UK).
Selection of WW domain against VEGFR-2 using CIS display therapeutic molecules or diagnostic reagents and compares favourably with other peptide scaffolds such as affibodies.
One advantage of the scaffold presented here is that the size is easily within the scope of solid phase peptide synthesis. Consequently, this offers the possibility of further optimisation through chemical synthesis including; unnatural amino acids, post-translational modifications ( phospho-or acetylated residues), and moieties for 'click chemistry' reactions etc., which are useful for improving affinities and stability.
Outside the surface modifications, we have also modified the domain through the introduction of a constraint to improve the stability and protease resistance of the framework. Linear peptides or peptide epitopes notoriously suffer from a poor resistance to protease hydrolysis, as evidenced by half-lives of only a few minutes (Vlieghe et al., 2010) . Cyclisation can be successful in circumventing this issue by limiting accessibility of the termini to amino-and carboxypeptidase degradation. Indeed, cyclisation of the Pin1 WW domain has been previously undertaken through use of a flexible glycine linker between backbone residues in the N-(residue 6) and C-termini (residue 39). The authors showed that a linker length of between 3 and 5 residues, with a distance between 10.5 and 17.5 Å , is optimal to stabilise the structure as shown by an increase in T m from 59 to 708C, while maintaining binding to its target phosphorylated peptide (monitored by CD). (Deechongkit and Kelly, 2002) .
Here, we chose positions 6 -36 and 4 -28 as these were deemed appropriately positioned for optimal cyclisation. Thus, the termini peptide cycB1_6 -36, and an internal staple peptide cyc-B1_4-28, where one end of the peptide is attached to a residue within loop 2, were created. Both cyclic structures were capable of folding and binding to VEGFR-2 with a similar affinity to linear WW-B1, suggesting that the binding surface is not adversely affected by cyclisation at these positions. However, the latter approach resulted in better improvement. Maintenance of binding, was unexpected as the link between residues Lys6 and Pro36 (Pro37 in WW-Pin1) includes Pro37 which is believed to be important for folding of the WW domain, forming a core with Trp11 and Asn26 (Socolich et al., 2005) , while the link between Glu4 and Thr28 (Thr29 in WW-Pin1) could potentially destabilise the p turn between the second and third b-strand (Jiang et al., 2001) .
One explanation for the improved half-life of cycB1_4-28 is that the trypsin/trypsin-like enzymes are unable to access the protease-sensitive sites within the peptide sequence, for example, chymotrypsin sites Trp11 and Trp15 and trypsin sites Lys13 and Arg20. Peptides corresponding to the molecular masses of fragments containing both cysteines were recovered from the stability tests of the cyclic and not the linear peptide, providing evidence of maintenance of this bridge in the plasma assay. However, some shorter peptides were also purified during the plasma assay (data not shown). Therefore, the disulphide bond between residues 4 and 28 offers some resistance to protease attack although this might be improved through alternative chemistry to a disulphide. Further work using a combinatorial approach, where a series of peptides are made in which the position of the cyclisation is systematically varied, might confirm whether or not a particular position in the scaffold is indeed beneficial for cyclisation and protease stability. Alternative strategies could be applied to the cyclisation of this scaffold, for example the use of codon reprogramming to introduce unnatural amino acids by ribosomal synthesis during expression and display (Freidinger, 2009; Kawakami et al., 2009) . This has been beyond the scope of the current work, but reprogramming the initiation event from fMet to N-chloroacetylamino acid to enable the formation of a thioether bond upon reaction with the thiol of a cysteine at the C-terminus, can be envisaged (Reid et al., 2012) .
In conclusion, these data show that the modified WW domain is a potentially useful scaffold for the selection of novel binding domains and for the creation of new proteinprotein interactions. This demonstrates the potential versatility of the WW domain as a novel binding module, which greatly expands the potential repertoire of non-natural target ligands for WW domains. We have also validated a strategy for the discovery of novel peptidic reagents that can find applications in the discovery, therapeutic or diagnostics fields. In particular, we have demonstrated the advantage of using CIS-display for rapid making and screening of a vast library of variants. We believe that this strategy is robust, versatile and will lend itself to many scaffolds, peptidic or larger, and should in the future yield new, potent and selective peptide ligands to a broad range of targets.
